Business Context and Reporting Period
This Form 8-K was filed by Aptevo Therapeutics Inc. on September 13, 2023. The report addresses a regulatory notice received from The Nasdaq Stock Market regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory notice.
- Stock Price Deficiency: The closing bid price of the Company's common stock was below $1.00 per share for the last 30 consecutive business days.
- Required Threshold: Nasdaq Listing Rule 5550(a)(2) requires a minimum closing bid price of $1.00 per share.
Material Changes
The material change reported is the receipt of a formal notice from Nasdaq staff indicating a failure to satisfy the Bid Price Requirement. This status change initiates a compliance period for the Company to restore its stock price to the required level.
Outlook, Risks, and Contingencies
Compliance Timeline: The Company has 180 calendar days, until March 11, 2024, to regain compliance. To succeed, the stock must close at or above $1.00 per share for a minimum of ten consecutive business days prior to the Compliance Date.
Contingencies and Risks:
- Second Compliance Period: If the Company fails to meet the initial deadline but meets other listing standards (such as market value of publicly held shares), it may be eligible for an additional 180-day period. This may require a reverse stock split.
- Delisting Risk: If the Company fails to regain compliance by the deadline and is not eligible for an extension, Nasdaq will issue a delisting notice.
- Appeal Uncertainty: The Company may appeal a delisting determination to the Nasdaq Listing Qualifications Panel, though there is no assurance of success.
Management Commentary: Management intends to actively monitor the closing bid price and evaluate available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of APVO common stock to assess proximity to the $1.00 threshold.
- Monitor the company's stock for ten consecutive days of trading at or above $1.00 to confirm compliance.
- Review future filings for announcements regarding a potential reverse stock split if the initial compliance period is missed.
- Check the company's market value of publicly held shares to determine eligibility for a second compliance period.